Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...
The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.
MedPage Today on MSN1d
ObesityWeek Roundup: Patients More Likely to Ration Weight-Loss DrugsSAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...
Medpage Today on MSN5d
Zepbound's Weight Loss, Cardiometabolic Benefits Hold Up at 3 YearsSAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...
A mixed sales report for Novo Nordisk’s GLP-1 megablockbuster drugs failed to quiet concerns Wednesday that investors may ...
"I'm using [Ozempic] off-label for a whole host of conditions — and have been for years," Dr. Caroline Messer, an ...
Dallas Morning News on MSN5d
FDA adds new warning to weight loss drugs including WegovyThe FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...
Losing weight on GLP-1 drugs like Ozempic isn't guaranteed. Experts reveal how to tell if yours isn't working and the next steps you should take to reach your weight loss goals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback